BLAINTRAVENOUSINJECTABLE
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
IMULDOSA (ustekinumab-srlf) by Accord Biopharma is igg1κ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the il-12 and il-23 cytokines. First approved in 2024.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMULDOSA (ustekinumab-srlf) is an IgG1κ monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23 cytokines, disrupting inflammatory signaling implicated in chronic immunological diseases. It is administered intravenously and represents a biosimilar or follow-on biological to the reference ustekinumab product. The drug targets conditions characterized by IL-12/IL-23–mediated inflammation, with Crohn's disease and ulcerative colitis as primary indications.
Growth
Early-stage post-launch product with moderate competitive pressure (30/100) suggests expanding commercial team needs for rapid market penetration.
Mechanism of Action
IgG1κ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on IMULDOSA offers entry into the high-value biologics/immunology space with exposure to launch dynamics, biosimilar competitive strategy, and managed care negotiations in gastroenterology. Roles emphasize commercial execution, market access, and patient outcomes rather than clinical development, with career growth tied to successful market penetration and lifecycle extension into adjacent indications.
Worked on IMULDOSA at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.